Communication between health-care professionals and individuals with cancer regarding the effects of treatment on sexual ...

Toxicity related to the systematic delivery of IL-12, a well-known and widely researched anti-tumor cytokine, has limited its ...

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.

Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...

Northwestern Medicine scientists have uncovered new details about the genetic structure of ovarian cancer stem cells, ...

Ovarian cancer—known as a silent killer due to its inability to showcase most of its symptoms—kills many women every year ...

Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory ...

A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer ...